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There are many other pathological similarities between degener-
ation of the IVD and osteoarthritis and is perhaps not surprising
that as we obtain an increased understanding of the disease
processes many similarities (as well as differences) are exposed
in the cell and molecular processes underlying OA and degener-
ation of the IVD.
This talk will describe some of these mechanisms and link them
to the origins of CLBP. It will also describe data from experimental
regenerative medicine to explain some aspects of the differences
in the behaviour of IVD cells in normal versus abnormal environ-
ments and explain how these influence thinking about applying
regenerative medicine to IVD repair and reconstruction.
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HYALURONATE FOR OSTEOARTHRITIS
Roy D. Altman
Hyaluronate (Hyaluronan, Hyaluronic acid, HA), a straight chain
polymer of the disaccharide D-glucuronic acid and β1, 3-N-
acetyl-D-glucosamine was purified in 1934. The use of HA for
intraarticular (IA) injections in osteoarthritis (OA) has been in
practice for over 10 years.
There are several HA formulations available, varying in size
of the polymer, some with crosslinking to increase their size
and viscosity. Although most are derived from rooster combs,
a few are derived from a bacterial source. Most of the clinical
trials have been in patients with OA of the knee. However,
more recent trials have examined the use in other joints with
OA, such as shoulder, hip, 1st CMC and ankle. The number of
injections in any series varies from one to five, depending on the
product. However, defining the number of injections in a series,
the spacing between the series and the amount of HA injected
have been empiric.
The mechanism of action of HA in OA is not known. HA of
low molecular weight has been shown to induce inflammation
in many organ systems through binding to several receptors;
eg CD44, RHAMM, Toll. HA of high molecular weight (eg >300
kDa) have been shown to interfere with the activation of these
receptors—suspected by the way the high molecular weight HA
binds to the receptors. Hence, in one proposed mechanism of
action, high molecular weight HA retards the activation of the
NFκB promoter system and the resultant multitude of inflamma-
tory mediators by the synovial cell or the chondrocyte.
There has been reluctance in accepting HA therapy for OA
based on the negative results of several clinical trials. IA therapy
presents several chalanges that accentuate the problems of OA
clinical trials, not the least of which is a large placebo effect that
reduces the effect size.
Bellamy has performed the most complete analysis of the clinical
trial results of HA in OA through the Cochrane mechanism.
He has determined that all the HAs have demonstrable benefit
with an effect size that is clinically relevant. Re-injection and
prolonged benefit have been demonstrated. Although there are
few trials that compare different HA products, no single HA
product has appeared superior to another.
There are a few clinical trials suggesting the IA HA may have
structure modifying properties.
Adverse events of IA HA are mostly limited to injection site reac-
tions, although pseudogout, pseudoseptic reactions and granu-
loma formation with repeated injections have been reported.
There are incomplete guidelines on when HA injections are to
be used. Clinical trials usually exclude patients with severe ra-
diographic changes, so that any delay to surgery is hypothetical.
At present, HAs are often used when other therapies have failed,
when the patient is a poor candidate for oral agents, when the
patient is intolerant of oral agents, when the patient is not a can-
didate for or declines surgery, and to delay surgical intervention.
There is minimal information on additive therapy of oral agents
and IA HA.
IA HA therapy is a useful and safe course of therapy for OA
of the knee and probably several other joints involved with OA.
Not all patients respond. Among those responding, many are
nearly pain free. More research is needed in several aspects of
this therapy, eg spacing of injections, timing of repeat series of
injections, significance of HA size, significance of crosslinking,
mechanism of action, HAs will continue to have a role in the
therapy of OA for the foreseeable future.
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SYMPTOMATIC SLOW ACTING DRUGS IN
OSTEOARTHRITIS: WORKSHOP AND PANEL
DISCUSSION: WHAT IS THE EVIDENCE? DIACEREIN IN
OSTEOARTHRITIS
Burkhard F. Leeb
Diacerein, a slow acting symptomatic drug in osteoarthritis
(SYSADOA) with interleukin-1 (IL-1β) inhibitory properties, is
widely used for for the treatment of osteoarthritis (OA). Like other
products of this group, diacerein has a slow onset of efficacy,
which becomes evident after 2–4 weeks of treatment and sig-
nificantly different versus placebo at 4 weeks in knee OA and
6 weeks in hip OA. It also has a long carry over effect once
treatment has stopped.
The compound was rated as a therapeutic option in OA with
evidence level 1b within the EULAR recommendations 2003,
and was highly recommended class A according to the experts
opinion [1].
An explanation for a slow onset of activity and long carry-over
effects once treatment is stopped may be due to the fact that
it has effects on underlying causes of OA. In vitro studies in
cultures of chondrocytes, synovial tissue and inflammatory cells,
have shown that therapeutic doses of both diacerein and its
active metabolite rhein inhibit the production and activity of the
pro-inflammatory and pro-catabolic cytokine IL-1β [2,3] both in
the superficial and deep layers of the cartilage [4] and in the
synovial membrane [5] from OA patients while stimulating the
production of growth factors such as TGF-β [6] and extracellular
cartilage matrix components such as proteoglycans [2,7] aggre-
cans [8], HA [9], and collagen type II [9,10] even in the presence
of IL-1β. Both agents also reduced IL-1β-induced MMP levels
and nitric oxide by chondrocytes [2,4,5,11] and reduced the syn-
thetic activities of OA osteoblasts which could be responsible
for abnormal subchondral bone remodelling occurring during the
course of OA [12].
The effects on pro-inflammatory, pro-catabolic cytokines seen in
the in vitro studies mentioned above have been confirmed in
vivo in an animal model [13] i.e. the granuloma-induced cartilage
breakdown model in the mouse. Diacerein was also shown to
down-regulate IL-1 levels in the synovial fluid of patients with
knee OA [14]. Studies in different animal models of OA [15–
17] showed that diacerein consistently reduced cartilage loss
in OA compared to untreated OA controls. In addition, a long-
term study in the ovine model of OA [18] showed that diacerein
treatment caused a significant increase in bone mineral density
measurements, in the density of the internal zone of the external
condyles and a decrease in the thickness of the subchondral
bone plate of the median zone of the tibial plateaux.
These postulated modes of action make the drug an interest-
ing option not only for symptom relief, but also for structure
modification in OA
Indeed, the ECHODIAH-trial, dealing with structure modification
in hip OA, came up with a reduction of the progression of hip
OA in Diacerein treated patients compared to the placebo group,
however, without symptomatic efficacy over three years [18].
